N. Bischofberger

1.2k total citations
24 papers, 930 citations indexed

About

N. Bischofberger is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, N. Bischofberger has authored 24 papers receiving a total of 930 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 13 papers in Virology and 10 papers in Epidemiology. Recurrent topics in N. Bischofberger's work include HIV Research and Treatment (13 papers), HIV/AIDS drug development and treatment (12 papers) and HIV/AIDS Research and Interventions (5 papers). N. Bischofberger is often cited by papers focused on HIV Research and Treatment (13 papers), HIV/AIDS drug development and treatment (12 papers) and HIV/AIDS Research and Interventions (5 papers). N. Bischofberger collaborates with scholars based in United States, Netherlands and Germany. N. Bischofberger's co-authors include Julie M. Cherrington, Andrew Mulato, Audrey Kinter, T A Wiltrout, Anthony S. Fauci, Jeff Lifson, Lindi M. Wahl, Lieve Naesens, M A Nowak and Alun L. Lloyd and has published in prestigious journals such as Journal of Virology, The Journal of Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

N. Bischofberger

24 papers receiving 897 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N. Bischofberger United States 14 580 527 322 182 160 24 930
W. Don Decker United States 11 639 1.1× 765 1.5× 300 0.9× 107 0.6× 199 1.2× 11 1.1k
Sherry L. Orloff United States 14 610 1.1× 547 1.0× 279 0.9× 130 0.7× 134 0.8× 18 929
Richard D. Sloan Canada 21 650 1.1× 785 1.5× 278 0.9× 377 2.1× 292 1.8× 37 1.2k
Julie Mori United Kingdom 14 1.0k 1.7× 948 1.8× 312 1.0× 332 1.8× 317 2.0× 25 1.7k
J L Champalimaud Portugal 4 578 1.0× 689 1.3× 306 1.0× 80 0.4× 241 1.5× 7 938
M. B. Vasudevachari United States 12 550 0.9× 693 1.3× 196 0.6× 126 0.7× 140 0.9× 21 861
J Leibowitch France 5 400 0.7× 567 1.1× 240 0.7× 139 0.8× 467 2.9× 10 1.1k
J L Martin United States 7 827 1.4× 772 1.5× 330 1.0× 246 1.4× 63 0.4× 8 1.1k
Béatrice Labrosse France 13 397 0.7× 464 0.9× 310 1.0× 186 1.0× 250 1.6× 18 856
Margaret I. Johnston United States 18 443 0.8× 585 1.1× 266 0.8× 520 2.9× 396 2.5× 47 1.3k

Countries citing papers authored by N. Bischofberger

Since Specialization
Citations

This map shows the geographic impact of N. Bischofberger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Bischofberger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Bischofberger more than expected).

Fields of papers citing papers by N. Bischofberger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Bischofberger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Bischofberger. The network helps show where N. Bischofberger may publish in the future.

Co-authorship network of co-authors of N. Bischofberger

This figure shows the co-authorship network connecting the top 25 collaborators of N. Bischofberger. A scholar is included among the top collaborators of N. Bischofberger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Bischofberger. N. Bischofberger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ahlström, Malin G., N. Bischofberger, Torkil Menné, et al.. (2024). Subclinical immune responses to nickel in sensitized individuals—a dose–response study. Contact Dermatitis. 91(1). 1–10. 3 indexed citations
2.
3.
Stahl‐Hennig, Christiane, Nicole Stolte, N. Bischofberger, et al.. (2001). Enhanced Cellular Immune Response and Reduced CD8+ Lymphocyte Apoptosis in Acutely SIV-Infected Rhesus Macaques after Short-Term Antiretroviral Treatment. Virology. 279(1). 221–232. 26 indexed citations
4.
Laver, W.G., N. Bischofberger, & R. G. Webster. (2000). The Origin and Control of Pandemic Influenza. Perspectives in biology and medicine. 43(2). 173–192. 23 indexed citations
5.
Rosenwirth, Brigitte, Willy Bogers, Ivonne G. Nieuwenhuis, et al.. (1999). An anti‐HIV strategy combining chemotherapy and therapeutic vaccination. Journal of Medical Primatology. 28(4-5). 195–205. 16 indexed citations
6.
Naesens, Lieve, et al.. (1997). Anti-retrovirus activity and pharmacokinetics in mice of bis(POC)-PMPA, the bis(isopropyloxycarbonyloxymethyl) oral prodrug of PMPA. Antiviral Research. 34(2). A50–A50. 3 indexed citations
7.
Bischofberger, N., et al.. (1997). Efficacy of GS 4104 in ferrets infected with influenza A virus. Antiviral Research. 34(2). A74–A74. 4 indexed citations
8.
Nowak, M A, Alun L. Lloyd, T A Wiltrout, et al.. (1997). Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. Journal of Virology. 71(10). 7518–7525. 228 indexed citations
9.
Dougherty, Joseph P., Andrew Mulato, Reza Oliyai, et al.. (1997). Synthesis, in Vitro Biological Evaluation and Oral Bioavailability of 9-[2-(Phosphonomethoxy)Propyl]Adenine (PMPA) Prodrugs. Antiviral chemistry & chemotherapy. 8(6). 557–564. 95 indexed citations
10.
Mendel, Dirk B., C. Y. Tai, Paul A. Escarpe, et al.. (1997). GS 4071 is a potent and selective inhibitor of the growth and neuraminidase activity of influenza A and B viruses in vitro. Antiviral Research. 34(2). A73–A73. 5 indexed citations
11.
Barnard, D. L., et al.. (1997). Acyclic Phosphonomethylether Nucleoside Inhibitors of Respiratory Viruses. Antiviral chemistry & chemotherapy. 8(3). 223–233. 12 indexed citations
12.
13.
Naesens, Lieve, Jan Balzarini, N. Bischofberger, & Erik De Clercq. (1996). Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. Antimicrobial Agents and Chemotherapy. 40(1). 22–28. 64 indexed citations
14.
KRAWCZYK, S. H., et al.. (1996). Inhibition of HIV-1 RNase H Activity by Nucleotide Dimers and Monomers. Antiviral chemistry & chemotherapy. 7(1). 37–45. 8 indexed citations
15.
Tsai, Che‐Chung, Kathryn E. Follis, A Sabó, Richard Grant, & N. Bischofberger. (1995). Efficacy of 9-(2-Phosphonylmethoxyethyl)adenine Treatment against Chronic Simian Immunodeficiency Virus Infection in Macaques. The Journal of Infectious Diseases. 171(5). 1338–1343. 24 indexed citations
16.
17.
Naesens, Lieve, Johan Neyts, Jan Balzarini, N. Bischofberger, & Erik De Clercq. (1995). Antiviral efficacy in mice of oral bis(POM)-PMEA, the Bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. Antiviral Research. 26(3). A276–A276. 2 indexed citations
18.
Tsai, Che‐Chung, Kathryn E. Follis, A Sabó, et al.. (1994). Preexposure Prophylaxis with 9-(2-Phosphonylmethoxyethyl)adenine against Simian Immunodeficiency Virus Infection in Macaques. The Journal of Infectious Diseases. 169(2). 260–266. 40 indexed citations
19.
Srinivas, R V, Brian L. Robbins, Michele Connelly, et al.. (1993). Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates. Antimicrobial Agents and Chemotherapy. 37(10). 2247–2250. 87 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by W. Don Decker Breakdown of academic impact, for papers by Sherry L. Orloff Breakdown of academic impact, for papers by Richard D. Sloan Breakdown of academic impact, for papers by Julie Mori Breakdown of academic impact, for papers by J L Champalimaud Breakdown of academic impact, for papers by M. B. Vasudevachari Breakdown of academic impact, for papers by J Leibowitch Breakdown of academic impact, for papers by J L Martin Breakdown of academic impact, for papers by Béatrice Labrosse Breakdown of academic impact, for papers by Margaret I. Johnston
Rankless by CCL
2026